Excellergy launched with a $70 million Series A led by Samsara Biocapital to advance a new class of allergy drugs called effector cell response inhibitors (ECRIs). The company says ECRIs work across multiple IgE‑mediated pathways to disarm effector cells without triggering mast cell or basophil activation, positioning the approach as a potential alternative or complement to existing anti‑IgE agents like omalizumab (Xolair). Management highlighted preclinical data and a plan to file an IND for a lead candidate in the near term, with the Series A funding earmarked for advancing programs into first‑in‑human studies. Excellergy’s founding scientific claims trace to structural IgE biology from Stanford and the University of Bern. Investors framed the round as a bet on category‑defining differentiation in allergy where faster onset and fuller control of effector responses could expand market share versus incumbent biologics.